Predictors of De-novo Development of Obstructive Sleep Apnea in Pregnancy
Predictors
1 other identifier
observational
450
1 country
1
Brief Summary
This study seeks to understand the physical, physiologic and biologic features that predispose a woman to the development of obstructive sleep apnea once they are exposed to the cardiopulmonary and metabolic physiological changes of pregnancy. Knowing these specific predictive factors can help identify a population at risk and guide clinicians to develop suitable targeting screening strategies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2016
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 21, 2016
CompletedFirst Posted
Study publicly available on registry
September 28, 2016
CompletedStudy Start
First participant enrolled
November 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2025
CompletedNovember 22, 2024
November 1, 2024
7.2 years
September 21, 2016
November 20, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Characteristics of participants who develop obstructive sleep apnea defined as an apnea hypopnea index >5 events per hour
The study will develop a model of biologic, physiologic and anthropometric measures that predict the development of obstructive sleep apnea apnea later in pregnancy compared to baseline in early pregnancy.
Up to 40 weeks
Eligibility Criteria
Pregnant women, 18 years or older, at less than 13 completed weeks of gestation and who have a BMI that is greater than 30 kg/m2 at recruitment.
You may qualify if:
- \<13 completed weeks of gestation
- BMI \>30 kg/m2 at recruitment
- \>18 years of age
- Ability to give informed consent
You may not qualify if:
- Twin pregnancies
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The Miriam Hospitallead
- Brown Universitycollaborator
- Rhode Island Hospitalcollaborator
- Women and Infants Hospital of Rhode Islandcollaborator
Study Sites (1)
The Miriam Hospital
Providence, Rhode Island, 02904, United States
Related Publications (2)
Bublitz MH, Nillni Y, Nugent NR, Sanapo L, Habr N, Bourjeily G. Posttraumatic stress disorder, diurnal cortisol, and ambulatory blood pressure in early and late pregnancy. J Trauma Stress. 2023 Feb;36(1):239-246. doi: 10.1002/jts.22895. Epub 2022 Dec 4.
PMID: 36464928DERIVEDSanapo L, Bublitz MH, Bai A, Mehta N, Messerlian GM, Catalano P, Bourjeily G. Association between sleep disordered breathing in early pregnancy and glucose metabolism. Sleep. 2022 Apr 11;45(4):zsab281. doi: 10.1093/sleep/zsab281.
PMID: 34999843DERIVED
Biospecimen
Blood samples will be stored for future testing
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ghada Bourjeily, MD
The Miriam Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor of Medicine
Study Record Dates
First Submitted
September 21, 2016
First Posted
September 28, 2016
Study Start
November 1, 2016
Primary Completion
December 30, 2023
Study Completion
May 1, 2025
Last Updated
November 22, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, ANALYTIC CODE
- Time Frame
- Data will be available within 12 months of study completion.
- Access Criteria
- Investigators data access requests will be reviewed by an independent review committee. Requestors will need to sign a data access agreement.
De-identified data for primary and secondary outcome measures will be made available.